Brief: Dermata Announces Achievement Of 50% Enrollment In Pivotal Dmt310 Phase 3 Star-1 Clinical Trial For Acne
17/07/2024 14:21
July 17 (Reuters) - Dermata Therapeutics Inc DRMA.O :
* DERMATA ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL
DMT310 PHASE 3 STAR-1 CLINICAL TRIAL FOR ACNE
* DERMATA THERAPEUTICS INC - STAR-1 TOPLINE RESULTS EXPECTED
IN Q1
OF 2025
Source text for Eikon: ID:
Further company coverage: DRMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview